相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
Yu Yang Ng et al.
CANCER GENE THERAPY (2022)
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
May Daher et al.
BLOOD (2021)
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18
Min Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
May Daher et al.
CANCER DISCOVERY (2021)
Two-step generation of mesenchymal stem/stromal cells from human pluripotent stem cells with reinforced efficacy upon osteoarthritis rabbits by HA hydrogel
Leisheng Zhang et al.
CELL AND BIOSCIENCE (2021)
CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients
Shi-Jiang Lu et al.
STEM CELLS TRANSLATIONAL MEDICINE (2021)
Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of On-Target, Off-Tumor Toxicity
Yinyin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
Chia-Ing Jan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
Xuan Guo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
Maxwell Y. Lee et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
Mark Gurney et al.
CANCERS (2021)
CAR-NK Cells in the Treatment of Solid Tumors
Ewa Wrona et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
Jing Pan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
Reza Elahi et al.
STEM CELL REVIEWS AND REPORTS (2021)
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma
Teng Wei et al.
ONCOIMMUNOLOGY (2021)
CAR-NK cells: the next wave of cellular therapy for cancer
May Daher et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
C. Quintarelli et al.
LEUKEMIA (2020)
Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer
Bihui Cao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells
Tatsuki Ueda et al.
CANCER SCIENCE (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
Yu Yang Ng et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
Zhiwei Hu
SCIENTIFIC REPORTS (2020)
Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear
Anastasios Karadimitris
CANCER CELL (2020)
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Ombretta Melaiu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children
Jing Pan et al.
LEUKEMIA (2020)
Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy
Loris Zamai et al.
CELLS (2020)
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Margery Gang et al.
BLOOD (2020)
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
Yoshifumi Baba et al.
CANCER SCIENCE (2020)
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity
Huang Zhu et al.
CELL STEM CELL (2020)
Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
Shuo Yang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Use of Cell and Genome Modification Technologies to Generate Improved Off-the-Shelf CAR T and CAR NK Cells
Michael A. Morgan et al.
FRONTIERS IN IMMUNOLOGY (2020)
CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman et al.
EBIOMEDICINE (2020)
Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
Isabella Monia Montagner et al.
CELLS (2020)
A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis
Chengui Lu et al.
MOLECULAR IMMUNOLOGY (2020)
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
Melissa M. Berrien-Elliott et al.
CANCER DISCOVERY (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
Natural killer cell-based immunotherapy for acute myeloid leukemia
Jing Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma
Qi Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis
Chaojie Li et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2020)
CAR-expressing NK cells for cancer therapy: a new hope
Jufeng Xia (Shunichi Arai) et al.
BIOSCIENCE TRENDS (2020)
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based Off-the-Shelf Acute Myeloid Leukemia Immunotherapies
Stephan Kloess et al.
HUMAN GENE THERAPY (2019)
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Lin Xiao et al.
MOLECULAR THERAPY (2019)
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
Yingxi Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan et al.
LEUKEMIA (2019)
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Katherine D. Cummins et al.
HAEMATOLOGICA (2019)
Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
Xiang Ao et al.
JOURNAL OF IMMUNOTHERAPY (2019)
The Natural Cytotoxicity Receptors in Health and Disease
Alexander David Barrow et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cancer and the Immune System: The History and Background of Immunotherapy
Maura Abbott et al.
SEMINARS IN ONCOLOGY NURSING (2019)
HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer
Xian Wu et al.
BULLETIN DU CANCER (2019)
Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer
Ramesh B. Batchu et al.
SURGERY (2019)
Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
Evelyn O. Ojo et al.
SCIENTIFIC REPORTS (2019)
Engineered T Cell Therapy for Cancer in the Clinic
Lijun Zhao et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng et al.
NATURE REVIEWS CANCER (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Bjorklund et al.
CLINICAL CANCER RESEARCH (2018)
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
May Daher et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Thrombopoietin knock-in augments platelet generation from human embryonic stem cells
Leisheng Zhang et al.
STEM CELL RESEARCH & THERAPY (2018)
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
Dhifaf Sarhan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
MSX2 Initiates and Accelerates Mesenchymal Stem/Stromal Cell Specification of hPSCs by Regulating TWIST1 and PRAME
Leisheng Zhang et al.
STEM CELL REPORTS (2018)
Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells
Masayuki Shiozawa et al.
BMC IMMUNOLOGY (2018)
Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy
Elizabeth L. Siegler et al.
CELL STEM CELL (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Qing Zhang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Jiao Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G
Sareetha Kailayangiri et al.
ONCOIMMUNOLOGY (2017)
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
Stephan Kloss et al.
HUMAN GENE THERAPY (2017)
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
K. H. Chen et al.
LEUKEMIA (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
Kevin G. Pinz et al.
ONCOTARGET (2017)
Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
Qing Zhang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Generation of Off-the-Shelf Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells
Jieming Zeng et al.
STEM CELL REPORTS (2017)
Phase 1 clinical trial of adoptive immunotherapy using off-the-shelf activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Michael Boyiadzis et al.
CYTOTHERAPY (2017)
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Harry Dolstra et al.
CLINICAL CANCER RESEARCH (2017)
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma
Sarah Oelsner et al.
CYTOTHERAPY (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors
Julia D. Suerth et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
Sabrina Genssler et al.
ONCOIMMUNOLOGY (2016)
Exploitation of natural killer cells for the treatment of acute leukemia
Rupert Handgretinger et al.
BLOOD (2016)
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Petra S. A. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan et al.
CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
Annette Romanski et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives
Jose Eduardo Vargas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
Xilin Chen et al.
ONCOTARGET (2016)
Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Yaewon Yang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
MSX2 mediates entry of human pluripotent stem cells into mesendoderm by simultaneously suppressing SOX2 and activating NODAL signaling
Qingqing Wu et al.
CELL RESEARCH (2015)
A novel method to expand large numbers of CD56+ natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation
Sumithira Vasu et al.
CYTOTHERAPY (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Toepfer et al.
JOURNAL OF IMMUNOLOGY (2015)
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma
Nadja Müller et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Richard W. Childs et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Advantages and applications of CAR-expressing natural killer cells
Wolfgang Glienke et al.
FRONTIERS IN PHARMACOLOGY (2015)
Utilizing chimeric antigen receptors to direct natural killer cell activity
David L. Hermanson et al.
FRONTIERS IN IMMUNOLOGY (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
Masaru Imamura et al.
BLOOD (2014)
Effect of tumor cells and tumor microenvironment on NK-cell function
Massimo Vitale et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Transfection of chimeric anti-CD 138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Hua Jiang et al.
MOLECULAR ONCOLOGY (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo
Zhenya Ni et al.
STEM CELLS (2014)
Are natural killer cells superior CAR drivers?
Hans Klingemann
ONCOIMMUNOLOGY (2014)
A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Yu-Hsiang Chang et al.
CANCER RESEARCH (2013)
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Jerome Galon et al.
IMMUNITY (2013)
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody
Ge Zhang et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice
Jeannette Cany et al.
PLOS ONE (2013)
Natural killer cells: a review of manufacturing and clinical utility
Scott A. Koepsell et al.
TRANSFUSION (2013)
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
Joachim Koch et al.
TRENDS IN IMMUNOLOGY (2013)
Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy
Lin Kang et al.
FRONTIERS IN IMMUNOLOGY (2013)
Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
Laurent Boissel et al.
ONCOIMMUNOLOGY (2013)
Cytokine activation induces human memory-like NK cells
Rizwan Romee et al.
BLOOD (2012)
Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
Christiane Sahm et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Natalia Lapteva et al.
CYTOTHERAPY (2012)
NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
Ruth Esser et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
Transposon-mediated BAC transgenesis in human ES cells
Maria Rostovskaya et al.
NUCLEIC ACIDS RESEARCH (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
Melissa A. Geller et al.
CYTOTHERAPY (2011)
Size matters: versatile use of PiggyBac transposons as a genetic manipulation tool
Adele Kim et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
Tolga Sutlu et al.
CYTOTHERAPY (2010)
Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion
Dongxia Xing et al.
JOURNAL OF IMMUNOTHERAPY (2010)
ITAM-mediated Signaling by the T-Cell Antigen Receptor
Paul E. Love et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki et al.
CANCER RESEARCH (2009)
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
Laurent Boissel et al.
LEUKEMIA RESEARCH (2009)
Cytokine-induced memory-like natural killer cells
Megan A. Cooper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation
Sandrine Meyer-Monard et al.
TRANSFUSION (2009)
Human leukocyte antigen-G and cancer immunoediting
Mirjana Urosevic et al.
CANCER RESEARCH (2008)
Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers
Africa Wallace et al.
CLINICAL CANCER RESEARCH (2008)
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
Liat Binyamin et al.
JOURNAL OF IMMUNOLOGY (2008)
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Anna Kruschinski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells
Tina Mueller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Brett K. Kaiser et al.
NATURE (2007)
In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection
Yan Zhang et al.
IMMUNOLOGY (2007)
Developmental pathways that generate natural-killer-cell diversity in mice and humans
Nicholas D. Huntington et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Activation, coactivation, and costimulation of resting human natural killer cells
Yenan T. Bryceson et al.
IMMUNOLOGICAL REVIEWS (2006)
Efficient gene transfer into primary human natural killer cells by retroviral transduction
H Guven et al.
EXPERIMENTAL HEMATOLOGY (2005)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
C Imai et al.
BLOOD (2005)
Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor
T Schirrmann et al.
LEUKEMIA RESEARCH (2005)
Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity
RA Wilcox et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
